Pancreatic Cancer Research

ResearcherUniversity of MiamiActive in the last 2 years

Supriya Srinivasan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0006-9320-6762; OpenAlex author ID A5075601806. Sources: OpenAlex.

Their work

Papers
9 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
22
Papers, trials and grants by year

2018: 1 paper · 2019: 2 papers · 2020: 1 paper · 2021: 2 papers · 2022: none · 2023: 1 paper · 2024: none · 2025: 2 papers

Papers 9

  1. CREB Drives Acinar to Ductal Cells Reprogramming and Promotes Pancreatic Cancer Progression in Preclinical Models of Alcoholic Pancreatitis. Co-author DOI 10.1016/j.jcmgh.2025.101606↗
  2. Targeting CREB remodels the immune microenvironment to enhance immunotherapy responses in pancreatic cancer First author DOI 10.64898/2025.12.04.691935↗
  3. Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer. Co-author DOI 10.1158/2767-9764.crc-22-0329↗
  4. Combined Blockade of MEK and CDK4/6 Pathways Induces Senescence to Improve Survival in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1535-7163.mct-19-1043↗
  5. Targeting Tumor-Stromal IL6/STAT3 Signaling through IL1 Receptor Inhibition in Pancreatic Cancer. Co-author DOI 10.1158/1535-7163.mct-21-0083↗
  6. Combined Src/EGFR Inhibition Targets STAT3 Signaling and Induces Stromal Remodeling to Improve Survival in Pancreatic Cancer. Co-author DOI 10.1158/1541-7786.mcr-19-0741↗
  7. Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer. First author DOI 10.1158/1535-7163.mct-18-0464↗
  8. New mechanistic insights into modifiable risk factors that promote pancreatic cancer. Co-author DOI 10.18632/oncotarget.26813↗
  9. Tobacco Carcinogen-Induced Production of GM-CSF Activates CREB to Promote Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-18-0579↗

Closest collaborators

The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Austin R. Dosch · 9 shared papers, 2018–2025 · strength 1.19
  2. Nagaraj S. Nagathihalli · 9 shared papers, 2018–2025 · strength 1.19
  3. Nipun B. Merchant · 8 shared papers, 2018–2025 · strength 1.03
  4. Siddharth Mehra · 6 shared papers, 2020–2025 · strength 0.88
  5. Jashodeep Datta · 3 shared papers, 2021–2025 · strength 0.50
  6. Michael Nathan VanSaun · 4 shared papers, 2018–2025 · strength 0.47
  7. Iago De Castro Silva · 3 shared papers, 2021–2025 · strength 0.47
  8. Samara P. Singh · 3 shared papers, 2021–2025 · strength 0.47
  9. Haleh Amirian · 2 shared papers, 2025 · strength 0.38
  10. Tulasigeri M. Totiger · 3 shared papers, 2018–2025 · strength 0.35
  11. Jason A. Castellanos · 3 shared papers, 2018–2021 · strength 0.27
  12. Brent A. Willobee · 2 shared papers, 2020–2021 · strength 0.23
  13. Anna Bianchi · 1 shared paper, 2025 · strength 0.20
  14. Kathleen E. DelGiorno · 1 shared paper, 2025 · strength 0.19
  15. Oliver Gene McDonald · 1 shared paper, 2025 · strength 0.19
  16. Vineet Kumar Gupta · 1 shared paper, 2025 · strength 0.19
  17. Eli Gilboa · 1 shared paper, 2023 · strength 0.16
  18. Jashodeep Datta · 1 shared paper, 2023 · strength 0.16
  19. Sulagna Banerjee · 1 shared paper, 2021 · strength 0.11
  20. Xi Chen · 1 shared paper, 2019 · strength 0.08
  21. Kumaraswamy Malleshappa Honnenahally · 1 shared paper, 2018 · strength 0.07
  22. Chanjuan Shi · 1 shared paper, 2018 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.